Placing

RNS Number:8700O
Celsis International PLC
20 August 2003



                            CELSIS INTERNATIONAL PLC

          Placing of 5,349,300 new ordinary shares at 29.5p per share


To meet institutional investor demand, Celsis International plc ("Celsis" or
"the Company"), the rapid microbial testing company, has issued 5,349,300 new
ordinary shares at 29.5p per share through a Placing by the Company's broker,
Seymour Pierce Limited.  The Placing shares represent 5 per cent of the enlarged
issued share capital of the Company.

Application has been made to the UKLA for the admission of the new ordinary
shares to the Daily Official List and to the London Stock Exchange for admission
to trading. Dealings in these new shares are expected to commence on 26 August
2003.


                                                                  20 August 2003




Enquiries:

Celsis International plc                                     Tel: [phone]
Jay LeCoque, Chief Executive Officer
Jenny Parsons, Corporate Communications

College Hill                                                 Tel: [phone]
Nicholas Nelson / Corinna Dorward




Notes to editors

Celsis International plc is a world leader in the development and supply of
rapid diagnostic and monitoring systems to detect and measure microbial
contamination in finished products bound for consumers.  It has successfully
developed tests for use in the pharmaceutical, cosmetic and toiletries, food and
beverage industries and is associated with some of the best-known high street
brands in these consumer areas.

These tests are based upon the years of research in enzyme technology that
employ numerous methods for the rapid detection of microbial contamination.  The
result is that microbial testing times are reduced from around five days to a
little over one day, thus lending significant cost advantages to Celsis'
customers.

Celsis International plc also has a leading cGMP laboratory services, supporting
the R&D and manufacturing based testing needs of the pharmaceutical,
biotechnology and personal care industries.  This business unit currently
operates primarily in the United States.

For more information on Celsis International plc go to www.celsis.com




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

IOEMGGZRMGKGFZM